KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Deferred Revenue (2018 - 2020)

Astrazeneca has reported Current Deferred Revenue over the past 3 years, most recently at $12.0 million for Q4 2020.

  • Quarterly results put Current Deferred Revenue at $12.0 million for Q4 2020, down 57.14% from a year ago — trailing twelve months through Dec 2020 was $12.0 million (down 57.14% YoY), and the annual figure for FY2020 was $12.0 million, down 57.14%.
  • Current Deferred Revenue for Q4 2020 was $12.0 million at Astrazeneca, down from $28.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for AZN hit a ceiling of $92.0 million in Q4 2018 and a floor of $12.0 million in Q4 2020.
  • Median Current Deferred Revenue over the past 3 years was $28.0 million (2019), compared with a mean of $44.0 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 69.57% in 2019 and later plummeted 57.14% in 2020.
  • Astrazeneca's Current Deferred Revenue stood at $92.0 million in 2018, then plummeted by 69.57% to $28.0 million in 2019, then plummeted by 57.14% to $12.0 million in 2020.
  • The last three reported values for Current Deferred Revenue were $12.0 million (Q4 2020), $28.0 million (Q4 2019), and $92.0 million (Q4 2018) per Business Quant data.